SLPI and cancer: Furthermore, SLPI (secretory leukocyte peptidase inhibitor), which belongs to the category of ECM regulators, is currently being tested to verify whether an increased SLPI level in the sera may serve as a biomarker of cancer progression (NCT04854343).